Business
TME Pharma advances its new investment strategy and signs LOI with German resources company
TME Pharma advances its new investment strategy and signs LOI with German resources company A further step toward investment diversification into potential cash-flow–generating assets A potential strategic investment in sustainable tailings reprocessing and environmental rehabilitation projects for precious metals with strong value-creation prospects. Upon successful completion of due diligence, the proposed transaction will be submitted to shareholders at an Extraordinary General Meeting.TME Ph
About this update from Tme Pharma N.v.
[{"type":"image","alt":"TME Pharma","displaySize":"","headline":null,"caption":"TME Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":168,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/5665fc99f3a9e9a142bd30e6b237f8f5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.52HUXCGIC_HLORVkbN8Pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTY4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/5665fc99f3a9e9a142bd30e6b237f8f5","width":168,"height":54}},"lazy":false},{"type":"text","content":"TME Pharma advances its new investment strategy and signs LOI with German resources company ","length":91,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"A further step toward investment diversification into potential cash-flow–generating assets ","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"A potential strategic investment in sustainable tailings reprocessing and environmental rehabilitation projects for precious metals with strong value-creation prospects.","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Upon successful completion of due diligence, the proposed transaction will be submitted to shareholders at an Extraordinary General Meeting.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"TME Pharma reaffirms its commitment to advancing its biotech assets, with discussions continuing in parallel with potential partners.","length":133,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":533,"olType":false},{"type":"text","content":"Berlin, Germany, November 05, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today the signing of a non-binding Letter of Intent (LOI) with a German resource development company (“GRDC”) for a potential collaboration and investment. This initiative marks a further step in TME Pharma’s investment diversification strategy, designed to build a sustainable value platform, generate future cash flows, and strengthen the Company’s long-term financial position. The intended Transaction under the LOI is subject to further negotiation with GRDC, due diligence, and shareholder approval.","length":732,"tagName":"p"},{"type":"text","content":"Deployment of a broader investment stra...